Melissa S. Egbertson
Merck & Co.
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Melissa S. Egbertson.
Proceedings of the National Academy of Sciences of the United States of America | 2002
Jay A. Grobler; Kara A. Stillmock; Binghua Hu; Marc Witmer; Peter J. Felock; Amy S. Espeseth; Abigail Wolfe; Melissa S. Egbertson; Michele Bourgeois; Jeffrey Y. Melamed; John S. Wai; Steve Young; Joseph P. Vacca; Daria J. Hazuda
The process of integrating the reverse-transcribed HIV-1 DNA into the host chromosomal DNA is catalyzed by the virally encoded enzyme integrase (IN). Integration requires two metal-dependent reactions, 3′ end processing and strand transfer. Compounds that contain a diketo acid moiety have been shown to selectively inhibit the strand transfer reaction of IN in vitro and in infected cells and are effective as inhibitors of HIV-1 replication. To characterize the molecular basis of inhibition, we used functional assays and binding assays to evaluate a series of structurally related analogs. These studies focused on investigating the role of the conserved carboxylate and metal binding. We demonstrate that an acidic moiety such as a carboxylate or isosteric heterocycle is not required for binding to the enzyme complex but is essential for inhibition and confers distinct metal-dependent properties on the inhibitor. Binding requires divalent metal and resistance is metal dependent with active site mutants displaying resistance only when the enzymes are evaluated in the context of Mg2+. The mechanism of action of these inhibitors is therefore likely a consequence of the interaction between the acid moiety and metal ion(s) in the IN active site, resulting in a functional sequestration of the critical metal cofactor(s). These studies thus have implications for modeling active site inhibitors of IN, designing and evaluating analogs with improved efficacy, and identifying inhibitors of other metal-dependent phosphotransferases.
Journal of Chromatography B | 2008
Christopher J. Welch; Mirlinda Biba; Philip J. Pye; Remy Angelaud; Melissa S. Egbertson
Owing to slow rotation of a sterically constrained dimethylamide substituent, two slowly interconverting enantiomers of a preclinical candidate for pharmaceutical development, 1, (6-(3-Chloro-4-fluoro-benzyl)-4-hydroxy-2-methyl-3,5-dioxo-2,3,5,6,7,8-hexahydro-[2,6]naphthyridine-1-carboxylic acid dimethylamide) are observed by chiral chromatography. Isolation of pure enantiomer by preparative chiral chromatography followed by enantiopurity analysis over time allowed for a study of the kinetics of enantiomer interconversion under a variety of conditions. Relatively slow racemization was observed in alcohol solvents, with a half life on the order of 5-10 h. A dramatic influence of aqueous buffer pH on racemization was noted, with higher pH leading to rapid racemization within a few minutes, and lower pH leading to essentially no racemization for periods up to a week. A hypothesis explaining this unusual effect of pH on carboxamide bond rotation is offered, and some suggestions for potential utility of such a system are considered.
Bioorganic & Medicinal Chemistry Letters | 2017
Anthony J. Roecker; Melissa S. Egbertson; Kristen L.G. Jones; Robert P. Gomez; Richard L. Kraus; Yuxing Li; Amy Jo Koser; Mark O. Urban; Rebecca Klein; Michelle K. Clements; Jacqueline Panigel; Christopher J. Daley; Jixin Wang; Eleftheria N. Finger; John Majercak; Vincent P. Santarelli; Irene Gregan; Matthew J. Cato; Tracey Filzen; Aneta Jovanovska; Ying-Hong Wang; Deping Wang; Leo A. Joyce; Edward C. Sherer; Xuanjia Peng; Xiu Wang; Haiyan Sun; Paul J. Coleman; Andrea K. Houghton; Mark E. Layton
The voltage-gated sodium channel Nav1.7 is a genetically validated target for the treatment of pain with gain-of-function mutations in man eliciting a variety of painful disorders and loss-of-function mutations affording insensitivity to pain. Unfortunately, drugs thought to garner efficacy via Nav1 inhibition have undesirable side effect profiles due to their lack of selectivity over channel isoforms. Herein we report the discovery of a novel series of orally bioavailable arylsulfonamide Nav1.7 inhibitors with high levels of selectivity over Nav1.5, the Nav isoform responsible for cardiovascular side effects, through judicious use of parallel medicinal chemistry and physicochemical property optimization. This effort produced inhibitors such as compound 5 with excellent potency, selectivity, behavioral efficacy in a rodent pain model, and efficacy in a mouse itch model suggestive of target modulation.
Bioorganic & Medicinal Chemistry Letters | 2015
Melissa S. Egbertson; Georgia B. McGaughey; Steven M. Pitzenberger; Shaun R. Stauffer; Craig A. Coburn; Shawn J. Stachel; Wenjin Yang; James C. Barrow; Lou Anne Neilson; Melody Mcwherter; Debra S. Perlow; Bruce Fahr; Sanjeev Munshi; Timothy J. Allison; Katharine M Holloway; Harold G. Selnick; Zhi-Qiang Yang; John Swestock; Adam J. Simon; Sethu Sankaranarayanan; Dennis Colussi; Katherine Tugusheva; Ming Tain Lai; Beth Pietrak; Shari Haugabook; Lixia Jin; I. W. Chen; Marie Holahan; Maria Stranieri-Michener; Jacquelynn J. Cook
The IC50 of a beta-secretase (BACE-1) lead compound was improved ∼200-fold from 11 μM to 55 nM through the addition of a single methyl group. Computational chemistry, small molecule NMR, and protein crystallography capabilities were used to compare the solution conformation of the ligand under varying pH conditions to its conformation when bound in the active site. Chemical modification then explored available binding pockets adjacent to the ligand. A strategically placed methyl group not only maintained the required pKa of the piperidine nitrogen and filled a small hydrophobic pocket, but more importantly, stabilized the conformation best suited for optimized binding to the receptor.
Bioorganic & Medicinal Chemistry Letters | 2018
Shawn J. Stachel; Melissa S. Egbertson; Jenny Miu-Chun Wai; Michelle R. Machacek; Dawn M. Toolan; John Swestock; Donnie M. Eddins; Vanita Puri; Georgia B. McGaughey; Hua-Poo Su; Debbie Perlow; Deping Wang; Lei Ma; Gopal Parthasarathy; John Reid; Pravien Abeywickrema; Sean M. Smith; Jason M. Uslaner
An internal HTS effort identified a novel PDE2 inhibitor series that was subsequently optimized for improved PDE2 activity and off-target selectivity. The optimized lead, compound 4, improved cognitive performance in a rodent novel object recognition task as well as a non-human primate object retrieval task. In addition, co-crystallization studies of close analog of 4 in the PDE2 active site revealed unique binding interactions influencing the high PDE isoform selectivity.
Proceedings of the National Academy of Sciences of the United States of America | 2004
Daria J. Hazuda; Neville J. Anthony; Robert P. Gomez; Samson M. Jolly; John S. Wai; Linghang Zhuang; Thorsten E. Fisher; Mark W. Embrey; James P. Guare; Melissa S. Egbertson; Joseph P. Vacca; Joel R. Huff; Peter J. Felock; Marc Witmer; Kara A. Stillmock; Robert Danovich; Jay A. Grobler; Michael D. Miller; Amy S. Espeseth; Lixia Jin; I-Wu Chen; Jiunn H. Lin; Kelem Kassahun; Joan D. Ellis; Bradley K. Wong; Wei Xu; Paul G. Pearson; William A. Schleif; Riccardo Cortese; Emilio A. Emini
Proceedings of the National Academy of Sciences of the United States of America | 2000
Amy S. Espeseth; Peter J. Felock; Abigail Wolfe; Marc Witmer; Jay A. Grobler; Neville J. Anthony; Melissa S. Egbertson; Jeffrey Y. Melamed; Steve Young; Terence G. Hamill; James L. Cole; Daria J. Hazuda
Journal of Medicinal Chemistry | 1992
George D. Hartman; Melissa S. Egbertson; Wasyl Halczenko; William L. Laswell; Mark E. Duggan; Robert L. Smith; Adel M. Naylor; Patricia D. Manno; Robert J. Lynch
Journal of Medicinal Chemistry | 2003
Linghang Zhuang; John S. Wai; Mark W. Embrey; Thorsten E. Fisher; Melissa S. Egbertson; Linda S. Payne; James P. Guare; Joseph P. Vacca; Daria J. Hazuda; Peter J. Felock; Abigail Wolfe; Kara A. Stillmock; Marc Witmer; Gregory Moyer; William A. Schleif; Lori J. Gabryelski; Yvonne M. Leonard; Joseph J. Lynch; Stuart R. Michelson; Steven D. Young
Journal of Medicinal Chemistry | 2000
John S. Wai; Melissa S. Egbertson; Linda S. Payne; Thorsten E. Fisher; Mark W. Embrey; Lekhanh O. Tran; Jeffrey Y. Melamed; H. Marie Langford; James P. Guare; Linghang Zhuang; Vanessa E. Grey; Joseph P. Vacca; M. Katharine Holloway; Adel M. Naylor-Olsen; Daria J. Hazuda; Peter J. Felock; Abigail Wolfe; Kara A. Stillmock; William A. Schleif; and Lori J. Gabryelski; Steven D. Young